Format

Send to

Choose Destination
Clin Cancer Res. 2015 Oct 1;21(19):4356-64. doi: 10.1158/1078-0432.CCR-14-3357. Epub 2015 May 26.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

Author information

1
Section of Prostate Cancer Research, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany. Institute of Pathology, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany.
2
Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
3
Department of Internal Medicine, Philipps-University of Marburg, Marburg, Germany.
4
Institute of Pathology, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany.
5
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
6
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
7
Department of Otorhinolaryngology/Head and Neck Surgery, University of Bonn, Bonn, Germany.
8
Section of Prostate Cancer Research, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany. Department of Otorhinolaryngology/Head and Neck Surgery, University of Bonn, Bonn, Germany.
9
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Department of Otolaryngology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
10
Department of Internal Medicine, Philipps-University of Marburg, Marburg, Germany. VA Eastern Colorado Healthcare System, Denver, Colorado.
11
Section of Prostate Cancer Research, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany. Institute of Pathology, University Hospital of Bonn, Center for Integrated Oncology Cologne-Bonn, Bonn, Germany. sven.perner1972@googlemail.com.

Abstract

PURPOSE:

FGFR1 copy-number gain (CNG) occurs in head and neck squamous cell cancers (HNSCC) and is used for patient selection in FGFR-specific inhibitor clinical trials. This study explores FGFR1 mRNA and protein levels in HNSCC cell lines, primary tumors, and patient-derived xenografts (PDX) as predictors of sensitivity to the FGFR inhibitor, NVP-BGJ398.

EXPERIMENTAL DESIGN:

FGFR1 status, expression levels, and BGJ398 sensitive growth were measured in 12 HNSCC cell lines. Primary HNSCCs (n = 353) were assessed for FGFR1 CNG and mRNA levels, and HNSCC TCGA data were interrogated as an independent sample set. HNSCC PDXs (n = 39) were submitted to FGFR1 copy-number detection and mRNA assays to identify putative FGFR1-dependent tumors.

RESULTS:

Cell line sensitivity to BGJ398 is associated with FGFR1 mRNA and protein levels, not FGFR1 CNG. Thirty-one percent of primary HNSCC tumors expressed FGFR1 mRNA, 18% exhibited FGFR1 CNG, 35% of amplified tumors were also positive for FGFR1 mRNA. This relationship was confirmed with the TCGA dataset. Using high FGFR1 mRNA for selection, 2 HNSCC PDXs were identified, one of which also exhibited FGFR1 CNG. The nonamplified tumor with high mRNA levels exhibited in vivo sensitivity to BGJ398.

CONCLUSIONS:

FGFR1 expression associates with BGJ398 sensitivity in HNSCC cell lines and predicts tyrosine kinase inhibitor sensitivity in PDXs. Our results support FGFR1 mRNA or protein expression, rather than FGFR1 CNG as a predictive biomarker for the response to FGFR inhibitors in a subset of patients suffering from HNSCC.

PMID:
26015511
PMCID:
PMC4592392
DOI:
10.1158/1078-0432.CCR-14-3357
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Supplementary concept, Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center